Diabetes, Metabolic Syndrome and Obesity

eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes

By Chen Su, Xumin Li, Shuang Wang, Dan Liu

ReviewInterventions

The paper

Chen Su, Xumin Li, Shuang Wang, Dan Liu

First Hospital of China Medical University

Diabetes, Metabolic Syndrome and Obesity, 10 Sep 2026

doi.org/10.2147/dmso.s621958 PubMed 42741732

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk